Handelsbanken Fonder Ab Kymera Therapeutics, Inc. Transaction History
Handelsbanken Fonder Ab
- $24.3 Billion
- Q1 2025
A detailed history of Handelsbanken Fonder Ab transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 16,500 shares of KYMR stock, worth $428,505. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,500
Previous 16,500
-0.0%
Holding current value
$428,505
Previous $664,000
31.93%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding KYMR
# of Institutions
187Shares Held
60.3MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$178 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$156 Million2.67% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$134 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$134 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$127 Million32.49% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.42B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...